Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmopressin ODT open-label study of nocturia and sleep quality in adults with nocturnal polyuria
2017-000808-22Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Sep 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of desmopressin in nocturnal polyuria (NP), sponsored by Ferring Pharmaceuticals. Primary endpoint: Correlation between change in nocturnal voids and NSQS total score at Week 12. Started Sep 2017; status: completed.
02
Drugs
desmopressin
03
Conditions
nocturnal polyuria (NP)
Beyond the preview
Go deeper on 2017-000808-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000808-22.